Investment Thesis
BetterLife Pharma is a pre-revenue pharmaceutical company in severe financial distress with minimal cash generation and unsustainable burn rate. With only $2.9K in revenue against $4.0M in operating losses and $3.6M negative free cash flow, the company faces imminent liquidity crisis given its $406.9K cash position and 0.15x current ratio.
Strengths
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Positive stockholders equity of $3.4M provides some balance sheet cushion
- Operating as a pharmaceutical company in high-value sector with potential for future value creation if pipeline succeeds
Risks
- Critically low liquidity with current ratio of 0.15x and only $406.9K cash against substantial operating burn
- Severe revenue deficit with $2.9K revenue insufficient to cover any operational costs, indicating pre-commercialization stage
- Unsustainable cash burn of $3.6M annually will deplete remaining cash reserves in approximately 1.4 months at current run rate
- Extreme negative margins (operating margin -138191%, net margin -20579%) with no path to profitability visible
- Stale financial data from October 2021 raises uncertainty about current financial position and runway
- Zero insider purchases in last 90 days suggests lack of management confidence
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway to assess solvency timeline
- Revenue growth from pharmaceutical pipeline advancement or partnerships
- Capital raise announcements or debt financing to extend operational runway
- Clinical trial progress and regulatory milestones for drug candidates
- Operating expense reduction initiatives or restructuring plans
Financial Metrics
Revenue
2.9K
Net Income
-601.5K
EPS (Diluted)
$-0.07
Free Cash Flow
-3.6M
Total Assets
7.1M
Cash
406.9K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-138,191.3%
Net Margin
-20,579.3%
ROE
-17.5%
ROA
-8.5%
FCF Margin
-121,805.5%
Balance Sheet & Liquidity
Current Ratio
0.15x
Quick Ratio
0.15x
Debt/Equity
0.00x
Debt/Assets
60.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T22:34:11.305902 |
Data as of: 2021-10-31 |
Powered by Claude AI